Key takeaways for Procter & Gamble stock today (4 December 2025)
- Share price: Procter & Gamble Company (The) (NYSE: PG) trades around $145–146 per share, down about 1% on the day and near its recent lows. [1]
- Near 2‑year low: PG hit its lowest level since late 2023 on 2 December after the CFO warned about a more volatile U.S. consumer backdrop. [2]
- Fundamentals still solid: Q1 FY2026 (quarter ended 30 September 2025) delivered 3% net sales growth, 2% organic growth and a 3% increase in core EPS to $1.99, beating expectations. [3]
- Guidance intact: Management is still guiding for low‑ to mid‑single‑digit EPS growth and 1–5% all‑in sales growth in FY2026, despite headwinds from tariffs (~$400m after tax) and commodities (~$100m). [4]
- Dividend powerhouse: P&G yields about 2.8–2.9% and has paid a dividend for roughly 135+ years with nearly 70 consecutive annual increases, positioning it firmly in the “Dividend King” camp. [5]
- Street view: Most Wall Street analysts rate PG a “Moderate Buy”, with 12‑month price targets clustered around $171–177, implying ~15–20% upside from current levels. [6]
- Quant models: Algorithmic forecasts see PG around $153–174 in 2025–2026, also pointing to mid‑teens percentage upside, but short‑term technical indicators skew bearish as of 4 December. [7]
- Flows & positioning: Fresh 13F filings today show some institutions trimming PG and others aggressively adding, while insiders have sold modest amounts into strength, underscoring a mixed but still broadly supportive institutional backdrop. [8]
If you’re seeing the name “Procter & Gamble Company (The) 3 stock” on certain European or structured‑product platforms, it typically refers to exposure to the same underlying NYSE‑listed PG shares (often via warrants or certificates) rather than a different class of equity. [9]
1. Procter & Gamble stock today: price, valuation & trading range
As of the U.S. close on 4 December 2025, The Procter & Gamble Company:
- Ticker: PG (NYSE) – also traded in Europe under symbols like PRG in Frankfurt and Xetra cross‑listings. [10]
- Last price: about $145.3 per share. [11]
- Market cap: roughly $340–343 billion, placing P&G among the largest global consumer staples companies. [12]
- 52‑week range: approximately $142.5 – $180.0, with the stock now trading close to the bottom of that range after recently printing a 52‑week low near $144. [13]
- Valuation: trailing P/E around 21–22x; forward P/E in the low‑20s. [14]
- Dividend yield: about 2.8–2.9%, based on an annualized dividend of ≈$4.23 per share. [15]
- Beta & volatility: very low beta (~0.2–0.4), reflecting defensive, low‑volatility characteristics versus the broader market. [16]
In plain English, PG is behaving like a defensive stock that has finally started to feel the macro stress: the share price has slid into the mid‑$140s, but the valuation is not “fire‑sale cheap” – it’s more like “reasonable for a high‑quality staple under pressure.”
2. Why PG hit a 2‑year low this week
The biggest near‑term story for Procter & Gamble stock is a sharp sentiment shift following CFO Andre Schulten’s comments at the Morgan Stanley Global Consumer & Retail Conference on 2 December 2025. [17]
Key points from those remarks:
- Schulten described the U.S. consumer environment as “more volatile” and “the most volatile we’ve seen in a long time.”
- P&G is seeing “significant” declines in U.S. sales volume and value in October, and he doesn’t expect November to look materially better. [18]
- He flagged several one‑two punches to demand:
- A prior port strike led retailers to stockpile inventory, making current year‑over‑year comparisons look weak.
- The federal government shutdown and delayed SNAP benefits (food‑assistance payments) have hit lower‑income consumers particularly hard. [19]
These comments landed just days after TS2.Tech framed P&G going into December as a “steady but tariff‑pressured compounder”, highlighting: TS2 Tech
- A planned $400m after‑tax tariff headwind in FY2026.
- Ongoing commodity cost pressures.
- Strength in higher‑income shoppers upgrading to premium brands, contrasted with trade‑down to private label among lower‑income households.
Following Schulten’s remarks:
- Investopedia reported that PG shares fell to their lowest level in roughly two years on 2 December, before partially recovering intraday. [20]
- Bloomberg/Zacks aggregates echoed the theme that U.S. sales have softened meaningfully and that P&G is now a key real‑time gauge of consumer stress. [21]
Put together, the 2‑year low is the market’s way of saying: “We still like the business, but the macro backdrop just got noticeably tougher.”
3. Q1 FY2026 earnings: slow‑and‑steady in a noisy environment
Before this latest bout of volatility, P&G’s Q1 FY2026 results (reported 24 October 2025) had actually reassured investors. [22]
Highlights:
- Net sales:$22.4 billion, up 3% year over year.
- Organic sales:+2%, driven by +1% price and +1% mix, with overall volumes flat. [23]
- Diluted EPS (GAAP):$1.95, up 21%, helped by lower restructuring charges versus the prior year. [24]
- Core EPS:$1.99, up 3%, beating consensus by roughly 5 percentage points according to MarketBeat’s recap. [25]
- Cash generation: about $5.4 billion in operating cash flow and $4.8 billion in net earnings for the quarter; adjusted free‑cash‑flow productivity above 100%. [26]
- Capital returns in Q1:
- $2.55 billion in dividends;
- $1.25 billion in share repurchases – nearly $3.8 billion returned to shareholders in just one quarter. [27]
By segment, P&G’s integrated brand portfolio is doing exactly what you’d expect in a choppy economy: [28]
- Beauty: organic sales up mid‑single‑digits, helped by premium hair‑care and skin‑care products.
- Grooming: low‑ to mid‑single‑digit organic growth, driven by innovation and mix in razors and appliances.
- Health Care: roughly flat, with premium oral‑care mix offset by some volume pressure.
- Fabric & Home Care and Baby, Feminine & Family Care: organic sales roughly flat, with price/mix gains offset by weaker volumes, especially in Europe.
In the FY2026 outlook, management kept guidance unchanged: [29]
- All‑in sales growth:+1% to +5% year over year.
- Organic sales growth:in‑line to +4%.
- Diluted EPS growth:+3% to +9% versus FY2025 EPS of $6.51.
- Core EPS: $6.83–$7.09, midpoint $6.96, implying about +2% growth versus FY2025 core EPS of $6.83.
At the same time, P&G now expects:
- ~$100m after‑tax commodity headwind;
- ~$400m after‑tax tariff headwind;
- Net headwind of ~$250m from higher net interest expense and tax rate;
- Partly offset by ~$300m favorable FX tailwind. [30]
The big picture: operationally, P&G continues to grind out low‑single‑digit volume and mid‑single‑digit EPS growth with strong cash flow. The problem is less about execution and more about macro, tariffs and valuation expectations.
4. Dividend, buybacks & “Dividend King” status
For income‑focused investors, Procter & Gamble remains one of the benchmark dividend stocks in global markets.
Dividend track record
- P&G has paid a dividend for over 135 consecutive years and has raised that dividend for 69–70 years in a row, qualifying as a Dividend King. [31]
- In July 2025, the board declared a quarterly dividend of $1.0568 per share, payable 15 August 2025. [32]
- With an annualized payout of roughly $4.23 per share, today’s mid‑$140s share price implies a yield just under 3%. [33]
2026 capital‑return plans
Management has been explicit about using P&G’s cash‑machine profile to reward shareholders:
- For FY2026, P&G expects to pay around $10 billion in dividends and to repurchase approximately $5 billion of common shares, for total capital returns of about $15 billion. [34]
MarketBeat and Zacks analyses both emphasize that: [35]
- The payout ratio sits in the mid‑60s% range on forward earnings – high enough to matter, but not so high that it constrains future dividend growth.
- Consensus expects low‑ to mid‑single‑digit EPS growth, broadly matching P&G’s historical dividend‑growth pace.
Put simply, unless something dramatic breaks in the business, the dividend looks well‑covered and likely to keep creeping higher year after year.
5. Wall Street analyst ratings & 12‑month price targets
There is no single “official” Procter & Gamble stock forecast, but several major aggregators paint a broadly similar picture.
Consensus ratings and price targets
- MarketBeat (based on 21 analysts) shows:
- Average 12‑month target:~$171.53
- Range:$153 (low) – $209 (high)
- Implied upside: about 18% from roughly $145.3.
- Consensus rating:“Moderate Buy.” [36]
- Benzinga (26 analysts surveyed) reports:
- Average target: about $176.72
- High / Low:$209 / $153
- Recent three‑rating average target: around $166.67, implying single‑digit upside in the nearer term.
- Consensus rating:“Hold” (Zacks Rank #3), reflecting valuation concerns after years of outperformance. [37]
- StockAnalysis.com (14 analysts):
- Average 12‑month target:$174.43, roughly 20% above today’s price.
- Consensus rating:“Buy.” [38]
Fundamental valuation views
Several recent deep‑dive pieces from MarketBeat, Seeking Alpha and others converge on a theme: [39]
- P&G now trades below its historical P/E average for a high‑quality staple and offers a yield near the top of its 10‑year range.
- Analysts expect mid‑single‑digit EPS compound growth over the next 3–5 years, driven by modest price/mix gains, cost savings and buybacks.
- In that framework, fair‑value estimates generally suggest 10–25% upside over a 12‑ to 24‑month horizon, assuming macro headwinds don’t worsen dramatically.
A separate Simply Wall St / Yahoo Finance‑linked analysis explicitly asks whether investors are undervaluing PG by around 21%, based on discounted cash‑flow estimates that produce a fair‑value range in the high‑$170s. [40]
Net‑net: Street research sees upside from current levels, but not the kind of multi‑bagger profile growth investors chase in higher‑beta sectors. The story is moderate capital appreciation plus a reliable ~3% yield.
6. Quant & algorithmic forecasts for PG stock
Alongside human analysts, several platforms publish model‑driven projections for Procter & Gamble stock. These are not guarantees, but they do show how quantitative models interpret today’s data.
Medium‑term price paths (2025–2028)
Stockscan.io projects: [41]
- 2025: average price around $173.95, implying ~+19% from ~$145.
- 2026: average around $172.02 (range $151–193), about +18% vs current.
- 2027: average around $176.67 (range $165–188), about +22% from current levels.
- 2028: average about $186.18 (range $173–200), implying roughly +28% gain vs today.
These models broadly assume that PG’s blend of slow growth, steady margins and ongoing buybacks supports a gentle upward drift in the share price over time.
CoinCodex, which leans heavily on technical indicators, offers a slightly different angle: [42]
- Short term (next 5 days): forecast prices in the $146.7–148.3 range, up roughly 1–2% from here.
- Full‑year 2025 channel: expected trading band between $146.7 and $159.1, with an average of ~$153.5, implying a ~9.5% potential return for the year versus current levels.
- Technical sentiment today:
- Overall stance “bearish”, with 26 bearish and 0 bullish signals across common moving averages and indicators as of 4 December 2025.
- All major daily SMAs and EMAs (from 3‑day through 200‑day) sit above the current price and flash “Sell.”
The short‑term message from quant models is mixed:
- Price‑based technicals say “trend is down, be careful.”
- Longer‑term statistical and fundamental models say “expect high single‑digit to low‑double‑digit annual returns, mostly from dividends plus modest price gains.”
7. Institutional & insider activity: what the big money is doing
Fresh 13F‑style disclosures published today (4 December 2025) give a real‑time snapshot of how professional investors are positioning in PG. [43]
Institutions: both buyers and sellers
MarketBeat highlights several notable moves in Q2 holdings:
- Panagora Asset Management
- Halved its PG stake (-50%), selling 26,619 shares and ending Q2 with 26,638 shares worth about $4.24m.
- The article notes that, despite trimming, Panagora remains invested alongside other large institutions such as Vanguard, Nordes Bank and Nuveen. [44]
- Great Diamond Partners LLC
- Increased its PG position by 540%, buying an additional 67,259 shares to own 79,710 shares valued around $12.7m.
- PG now makes up about 2.7% of the firm’s portfolio and stands as its 7th largest holding, indicating strong conviction. [45]
- Baird Financial Group Inc.
- Trimmed its stake by a modest 3.5%, selling 59,511 shares but still holding 1.64 million shares worth about $262m (roughly 0.07% of the company). [46]
Across these and other filings:
- Institutions and hedge funds collectively own about 66% of PG’s float, with Vanguard alone holding over 233 million shares, worth more than $37 billion at recent prices. [47]
The takeaway: professional money is not abandoning PG; it is rebalancing, with some funds taking profits or reallocating, while others lean into the recent weakness as a long‑term entry point.
Insider selling
The same MarketBeat reports note that:
- Executives including CEO Gary A. Coombe and CEO Jennifer L. Davis (Health Care), as well as executive Susan Street Whaley, sold relatively small parcels (a few thousand shares each) around $152 in early October.
- Over the last 90 days, insiders have sold about 30,000 shares, worth roughly $4.6m, with insiders owning only about 0.2% of outstanding shares. [48]
Given P&G’s size and long‑standing equity‑comp programs, this looks like routine diversification rather than a strong directional signal, but in the context of a weak tape it reinforces that insiders are not aggressively buying the dip either.
8. Fundamentals & longer‑term thesis for “Procter & Gamble Company (The) 3 stock”
Whether you access the company via NYSE:PG or structured products labeled something like “Procter & Gamble Company (The) 3”, the core investment case rests on the same underlying business.
Business profile in brief
P&G is a global consumer‑goods powerhouse with leading brands across: [49]
- Beauty: Pantene, Head & Shoulders, Olay, SK‑II
- Grooming: Gillette, Venus, Braun
- Health Care: Oral‑B, Crest, Vicks, Pepto‑Bismol
- Fabric & Home Care: Tide, Ariel, Downy, Febreze, Swiffer, Cascade
- Baby, Feminine & Family Care: Pampers, Luvs, Always, Tampax, Charmin, Bounty
Financially, in fiscal 2025 P&G generated: [50]
- Revenue: about $84.28 billion, up slightly (~0.3%) vs the prior year.
- Net income:$15.68 billion, up about 7.5% year over year.
This mix of slow but steady top‑line growth, resilient margins and strong cash flow is exactly what long‑term dividend investors typically want.
Bullish arguments
- Defensive demand: consumers still need detergent, diapers and toothpaste in weak economies, which gives PG more earnings resilience than cyclical sectors.
- Pricing power & brand strength: premium products (e.g., higher‑end haircare or skincare) are supporting mix and pricing even as volumes come under pressure in some segments. [51]
- Capital‑return engine: a 2.8–2.9% yield, decades‑long dividend growth and $15b annual capital returns (dividends + buybacks) provide a solid base for total returns. [52]
- Valuation reset: after several years of sideways trading and underperformance versus the S&P 500, PG now trades at a discount to its historical P/E and near the lower end of its 52‑week range, which multiple analysts argue sets up moderate upside over the next few years. [53]
Bearish / risk factors
- Macro & consumer stress: the CFO’s December comments underline that lower‑income U.S. consumers are under pressure, with trade‑down to store brands and weaker volumes. That could cap near‑term growth and force more promotions. [54]
- Tariffs & cost inflation: P&G expects half a billion dollars in after‑tax cost headwinds from tariffs and commodities in FY2026. That’s a meaningful drag on margins that must be offset by price, mix and productivity gains. [55]
- Job cuts & restructuring: in June 2025 P&G announced a restructuring plan including about 7,000 job cuts over two years, largely tied to the new tariff environment and broader efficiency efforts. While this should improve margins in time, it introduces execution and morale risks. [56]
- Limited growth profile: even bullish projections mostly talk about mid‑single‑digit EPS CAGR, not double‑digit growth. Investors paying more than 20x earnings for this must be comfortable with a “slow compounding” story. [57]
In summary, Procter & Gamble Company (The) 3 stock (i.e., exposure to PG) still looks like a high‑quality, low‑volatility compounder, but current events have shifted the narrative from “bulletproof staple” to “staple under visible macro strain.”
9. What to watch next (December 2025 – 2026)
If you are following PG closely from 4 December 2025 onward, some key catalysts and monitoring points include: [58]
- Tariff developments
- Any changes in trade policy or tariff negotiations that affect P&G’s $400m headwind could materially shift earnings expectations.
- Consumer‑staples sector flows
- Sector ETFs and staples broad‑based flows remain soft; a rotation back into defensive names could lift PG even if its own numbers only meet guidance.
- Next earnings prints (Q2 & Q3 FY2026)
- The market will want to see whether the October/November volume weakness is a blip or the start of a longer trend.
- Watch for updated guidance: confirmation or tweak of the current EPS range will be important.
- Dividend declaration in early 2026
- Based on history, investors will look for another modest dividend increase, reinforcing the Dividend King narrative.
- Institutional positioning & insider activity
- Follow whether large holders continue to accumulate into weakness, or whether trimming accelerates if the macro picture deteriorates.
10. Bottom line (not financial advice)
As of 4 December 2025, Procter & Gamble’s share price tells a simple story:
- The stock is cheap relative to its own history and close to a 2‑year low,
- But not cheap in absolute terms, given a low‑growth, tariff‑pressured backdrop.
Most fundamental and quantitative analyses converge on a similar conclusion:
Over the next 12–24 months, PG is likely to deliver mid‑single‑digit annual EPS growth plus a ~3% dividend, with a decent chance of 10–20% price appreciation if macro headwinds don’t worsen.
For:
- Long‑term, income‑oriented investors, today’s pullback in Procter & Gamble Company (The) 3 stock/PG stock may look like an opportunity to accumulate a defensive dividend compounder at a more reasonable valuation.
- Short‑term traders and tactically minded investors should be aware that technical indicators are still bearish, and the CFO has just raised the volume on near‑term demand risks in the U.S.
As always, this article is for information and education only. It is not investment advice or a recommendation to buy or sell any security. Consider your own objectives, time horizon and risk tolerance, and consult a licensed financial professional before making investment decisions.
References
1. www.investing.com, 2. www.investopedia.com, 3. us.pg.com, 4. us.pg.com, 5. www.pginvestor.com, 6. www.marketbeat.com, 7. stockscan.io, 8. www.marketbeat.com, 9. www.gspriips.eu, 10. stockanalysis.com, 11. www.investing.com, 12. www.tradingview.com, 13. www.marketbeat.com, 14. www.marketbeat.com, 15. us.pg.com, 16. www.tradingview.com, 17. www.investopedia.com, 18. www.investopedia.com, 19. www.investopedia.com, 20. www.investopedia.com, 21. www.chartmill.com, 22. us.pg.com, 23. us.pg.com, 24. us.pg.com, 25. us.pg.com, 26. us.pg.com, 27. us.pg.com, 28. us.pg.com, 29. us.pg.com, 30. us.pg.com, 31. www.pginvestor.com, 32. us.pg.com, 33. www.marketbeat.com, 34. us.pg.com, 35. www.marketbeat.com, 36. www.marketbeat.com, 37. www.benzinga.com, 38. stockanalysis.com, 39. www.marketbeat.com, 40. finance.yahoo.com, 41. stockscan.io, 42. coincodex.com, 43. www.marketbeat.com, 44. www.marketbeat.com, 45. www.marketbeat.com, 46. www.marketbeat.com, 47. www.marketbeat.com, 48. www.marketbeat.com, 49. en.wikipedia.org, 50. stockanalysis.com, 51. us.pg.com, 52. us.pg.com, 53. www.marketbeat.com, 54. www.investopedia.com, 55. us.pg.com, 56. en.wikipedia.org, 57. www.marketbeat.com, 58. us.pg.com
